Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma

Cortés, José R.; Rivas, María Dolores Megías; Molina–Infante, Javier; González-Núñez, María; Perez-G, Moises; Masa, Juan F.; Sánchez, Juan F.; Zamorano, José Luís

doi:10.1016/j.jaci.2009.06.023

Cited by 50 publications

(46 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 were shown to inhibit in vitro IL-4 and IL-13 signaling STAT6 in murine asthma, reducing significantly the presence of inflammatory cells in bronchoalveolar lavage fluid and lung sections, including eosinophils [56]. In 2013, an experimental study demonstrated that omeprazole blocked Th2 cytokine-stimulated eotaxin-3 expression in oesophageal squamous cell cultures from both GORD and EoE patients [57].…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis

Molina–Infante

Rhijn

2015

Best Practice & Research Clinical Gastroenterology

Self Cite

View full text Add to dashboard Cite

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis

Molina–Infante

Rhijn

2015

Best Practice & Research Clinical Gastroenterology

Self Cite

View full text Add to dashboard Cite

“…Further more, lansoprazole treatment was described to down-regulate 1 and 2 signaling pathways in the human gastric mucosa [63] and to be associated with decreased levels of proin ammatory cytokines such as interleukin(IL-)6, IL-8 and tumor necrosis factor-(TNF-)α in cultured tracheal epithelial cells [64]. Interestingly, PPIs were also reported to inhibit IL-4 and IL-13 signaling via STAT6 (signal transducer and activator of transcription 6) [65] and in PPI-REE a marked reduction of eotaxin-3, IL-13, IL-5 mRNA expression was observed a er PPI treatment [66].…”

Section: Acid Suppression Medication and The Immune Responsementioning

confidence: 99%

Acid suppression therapy and allergic reactions

Untersmayr¹

2015

Allergo J

View full text Add to dashboard Cite

e development of pharmaceutical agents reducing gastric acidity such as sucralfate, histamine 2 (H2) receptor blockers, and proton pump inhibitors (PPIs) has been a milestone for the treatment of dyspeptic disorders. However, due to current prescription habits resulting in overuse of these potent drugs as well as over-the-counter (OTC) availability associated with self-medication, substantial health concern is related to the mechanisms of drug action as well as known side e ects in uencing gastrointestinal physiology. More than a decade ago, the rst study appeared reporting an association between anti-ulcer drug intake and food allergy development. Since then, several experimental and human studies veri ed this correlation, demonstrating that acid suppressive drugs not only in uence the sensitization capacity of orally ingested proteins, but also represent a risk factor for food allergic patients. Additionally, gastric acid suppression was reported to increase the risk for development of drug hypersensitivity reactions. ese consequences of anti-ulcer drug intake might on the one hand be associated with direct in uence of these drugs on immune responses. On the other hand reduction of gastric acidity leads to impaired gastrointestinal protein degradation. Nevertheless, also disruption of the gastrointestinal barrier function, changes in microbiome, or lack of tolerogenic peptic digests might contribute to the connection between anti-ulcer drug intake and allergic reaction. erefore, these drugs should only be prescribed based on a precise gastroenterological diagnosis taking into consideration allergological mechanisms to ensure patients' safety.Cite this as: Untersmayr E. Acid suppression therapy and allergic reactions.

show abstract

“…Selective STAT6 blockers are also under preclinical development (Dubey et al, 2011;Martinez-Nunez et al, 2011;Matsunaga et al, 2011;Nagashima et al, 2008;Oh et al, 2010;Tian et al, 2011;Zhou et al, 2012) and some of them are effective in animal models of asthma (Chiba et al, 2009a;Cortes et al, 2009;Darcan-Nicolaisen et al, 2009;McCusker et al, 2007;, but there is still a complete absence of studies on STAT6 blockers published on human asthmatics.…”

Section: Stats In the Pathogenesis Of Bronchial Asthmamentioning

confidence: 99%

Role of Transcription Factors in the Pathogenesis of Asthma and COPD

Caramori¹,

Casolari²,

Adcock

2013

Cell Communication & Adhesion

View full text Add to dashboard Cite

Infl ammation is a central feature of asthma and chronic obstructive pulmonary disease (COPD). Despite recent advances in the knowledge of the pathogenesis of asthma and COPD, much more research on the molecular mechanisms of asthma and COPD are needed to aid the logical development of new therapies for these common and important diseases, particularly in COPD where no effective treatments currently exist. In the future the role of the activation/repression of different transcription factors and the genetic regulation of their expression in asthma and COPD may be an increasingly important aspect of research, as this may be one of the critical mechanisms regulating the expression of different clinical phenotypes and their responsiveness to therapy, particularly to anti-infl ammatory drugs.

show abstract

Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma

Cited by 50 publications

References 9 publications

Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis

Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis

Acid suppression therapy and allergic reactions

Role of Transcription Factors in the Pathogenesis of Asthma and COPD

Contact Info

Product

Resources

About